Without using the words “universal” or “nationwide,” a U.S. district judge granted a preliminary injunction July 1 to stop the Department of Health and Human Services’ (HHS) reorganization plan, along with any workforce reduction that’s part of the plan.
While the first meeting of the U.S. CDC’s newly minted Advisory Committee for Immunization Practices (ACIP) is now recent history, questions about the makeup of the committee and its future direction remain unanswered.
The joining of psychedelic specialists Beckley Psytech Ltd. and Atai Life Sciences can now go ahead after the pair announced positive top-line results from the phase IIb study of BPL-003, an intranasal formulation of 5-MeO-DMT benzoate.
Hong Kong’s Department of Health (DH) announced plans to establish a new medical products regulatory agency called the Hong Kong Centre for Medical Products Regulation (CMPR) by the end of 2026.
Taiwan’s Hanchorbio Inc. is out-licensing its breakthrough checkpoint inhibitor, HCB-101, to Shanghai Henlius Biotech Inc. in a deal worth more than $200 million.
Torrent Pharmaceutical Ltd. will buy J. B. Chemicals and Pharmaceuticals Ltd. (JB Pharma) from private equity firm KKR & Co. Inc. at an equity valuation of ₹256.89 billion (US$3 billion), which will then merge into one entity under Torrent Pharma.
Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting up-front, near-term payments and R&D funding, could end up with about $1.5 billion in milestones and options payments plus tiered royalties on net sales.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Achieve Life Sciences, BMS, Innovent, Omeros, Schrödinger.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aicella, Biocryst, Calico, Channel, Invetech, Mabwell, Neopharmed, Turnstone, Xoma.
RSS
